HC-7366 + Nivolumab for Kidney Cancer

This trial tests whether a combination of drugs—specifically HC-7366 (an experimental treatment) and nivolumab, with or without ipilimumab—can help control clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. The researchers aim to determine if these drugs together can better manage the cancer's progression. Participants diagnosed with stage IV metastatic ccRCC, who have either not received prior treatment or have experienced cancer progression after certain treatments, may be suitable candidates. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. However, if you are on certain treatments like small molecule kinase inhibitors, you may need to stop them at least 2 weeks before starting the trial. It's best to discuss your specific medications with the trial team.

Research is testing the safety and effectiveness of combining HC-7366 and nivolumab for treating kidney cancer. Earlier studies have examined HC-7366 with other treatments, such as belzutifan, focusing on safety and patient tolerance. These studies are in the early stages, so researchers are still learning about its safety.

More information is available about the combination of nivolumab and ipilimumab. This combination has received approval in some places for treating certain types of kidney cancer, suggesting it is generally well-tolerated. However, researchers are still exploring the safety of adding HC-7366 to this mix.

Researchers are excited about these treatments because HC-7366, when combined with Nivolumab and potentially Ipilimumab, may offer a fresh approach for kidney cancer. Unlike standard treatments that often focus solely on immune checkpoint inhibitors like Nivolumab or Ipilimumab, HC-7366 could introduce a novel mechanism to bolster the immune response against cancer cells. This combination might enhance the effectiveness of the treatments, potentially leading to improved outcomes for patients. The unique aspect of HC-7366 being administered orally (PO) also offers a different delivery method that could improve patient convenience and compliance.

Research shows that using HC-7366 with nivolumab might help manage clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. HC-7366 reduces certain proteins that cancer cells need, potentially slowing the cancer's growth. Nivolumab enhances the immune system's ability to fight cancer. In this trial, participants in the Doublet Cohort will receive treatment with nivolumab and HC-7366.